TWI895442B - 咪唑并嗒嗪化合物及其用途 - Google Patents

咪唑并嗒嗪化合物及其用途

Info

Publication number
TWI895442B
TWI895442B TW110121255A TW110121255A TWI895442B TW I895442 B TWI895442 B TW I895442B TW 110121255 A TW110121255 A TW 110121255A TW 110121255 A TW110121255 A TW 110121255A TW I895442 B TWI895442 B TW I895442B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compounds
cancer
Prior art date
Application number
TW110121255A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214660A (zh
Inventor
淳 潘
白瑀
吳亮星
文清 姚
Original Assignee
美商英塞特公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商英塞特公司 filed Critical 美商英塞特公司
Publication of TW202214660A publication Critical patent/TW202214660A/zh
Application granted granted Critical
Publication of TWI895442B publication Critical patent/TWI895442B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110121255A 2020-06-12 2021-06-10 咪唑并嗒嗪化合物及其用途 TWI895442B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
US63/038,410 2020-06-12

Publications (2)

Publication Number Publication Date
TW202214660A TW202214660A (zh) 2022-04-16
TWI895442B true TWI895442B (zh) 2025-09-01

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110121255A TWI895442B (zh) 2020-06-12 2021-06-10 咪唑并嗒嗪化合物及其用途

Country Status (17)

Country Link
US (2) US11840546B2 (https=)
EP (1) EP4165051A1 (https=)
JP (1) JP2023530088A (https=)
KR (1) KR20230025434A (https=)
CN (1) CN115956081A (https=)
AR (1) AR122587A1 (https=)
AU (1) AU2021288107A1 (https=)
BR (1) BR112022025191A2 (https=)
CA (1) CA3184811A1 (https=)
CL (1) CL2022003453A1 (https=)
CO (1) CO2022017969A2 (https=)
EC (1) ECSP22093652A (https=)
IL (1) IL298248A (https=)
MX (1) MX2022015493A (https=)
PE (1) PE20230491A1 (https=)
TW (1) TWI895442B (https=)
WO (1) WO2021252781A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136634A1 (en) * 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
AR068877A1 (es) 2007-10-17 2009-12-09 Novartis Ag Derivados heterociclicos de imidazol
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
MX2019002951A (es) 2016-09-15 2019-09-11 Armstrong World Ind Inc Sistema de techo con movimiento aereo.
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018136634A1 (en) * 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors

Also Published As

Publication number Publication date
CN115956081A (zh) 2023-04-11
JP2023530088A (ja) 2023-07-13
WO2021252781A1 (en) 2021-12-16
CA3184811A1 (en) 2021-12-16
AR122587A1 (es) 2022-09-21
IL298248A (en) 2023-01-01
EP4165051A1 (en) 2023-04-19
US20240083918A1 (en) 2024-03-14
KR20230025434A (ko) 2023-02-21
ECSP22093652A (es) 2023-02-28
AU2021288107A1 (en) 2022-12-15
US20210388003A1 (en) 2021-12-16
CO2022017969A2 (es) 2023-02-27
US11840546B2 (en) 2023-12-12
CL2022003453A1 (es) 2023-05-26
BR112022025191A2 (pt) 2023-03-07
TW202214660A (zh) 2022-04-16
MX2022015493A (es) 2023-03-21
PE20230491A1 (es) 2023-03-23

Similar Documents

Publication Publication Date Title
US11492354B2 (en) Indazole compounds and uses thereof
US11591329B2 (en) Bicyclic heterocycles as FGFR inhibitors
US12441731B2 (en) Pyrazolopyrimidine compounds and uses thereof
JP7723068B2 (ja) アクチビン受容体様キナーゼ－２の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
TWI895442B (zh) 咪唑并嗒嗪化合物及其用途
EA046773B1 (ru) Соединения имидазопиридазина, активные в качестве ингибиторов alk2
EA050836B1 (ru) Соединения имидазопиридазина и их применения
HK40057772B (en) Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
HK40057772A (en) Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators